Used in research and development of immunotherapies targeting the B7-H4 (VTCN1) protein, which is overexpressed in several solid tumors including ovarian, breast, and pancreatic cancers. This reference antibody serves as a critical tool for validating assays, calibrating detection methods, and supporting the development of therapeutic antibodies and diagnostic tests. It enables accurate measurement of B7-H4 expression levels in tissue and cell samples, aiding in patient stratification and biomarker studies. Due to its high specificity, it supports preclinical evaluation of drug candidates that modulate the B7-H4 pathway to restore anti-tumor immune responses.